minimal Common Oncology Data Elements (mCODE) Implementation Guide
4.0.0-ballot - STU4 Ballot United States of America flag

This page is part of the HL7 FHIR Implementation Guide: minimal Common Oncology Data Elements (mCODE) Release 1 - US Realm | STU1 (v4.0.0-ballot: STU4 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 4.0.0. For a full list of available versions, see the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Patient Information
... 3 Disease Characterization
... 4 Assessment
... 5 Genomics
... 6 Treatments
... 7 Outcomes
... 8 Conformance Expectations
... 9 Identifying In-Scope Patients
... 10 Profile Conformance
... 11 Terminology
... 12 Data Dictionary
... 13 Profiles
... 14 Extensions
... 15 Value Sets
... 16 Code Systems
... 17 Capability Statements
... 18 Artifacts Summary
.... 18.1 mCODE Data Receiver CapabilityStatement: Get in-scope patients (and associated Conditions) using _include
.... 18.2 mCODE Data Receiver CapabilityStatement: Get in-scope patients using reverse chaining
.... 18.3 mCODE Data Receiver: Get Bundle for a Patient
.... 18.4 mCODE Data Receiver: Get Conditions then Patients
.... 18.5 mCODE Data Receiver: Get Patients in Group
.... 18.6 mCODE Data Sender CapabilityStatement: Get in-scope patients (and associated Conditions) using _include
.... 18.7 mCODE Data Sender CapabilityStatement: Get in-scope patients using reverse chaining
.... 18.8 mCODE Data Sender: Get Bundle for a Patient
.... 18.9 mCODE Data Sender: Get Conditions then Patients
.... 18.10 mCODE Data Sender: Get Patients in Group
.... 18.11 Fetch mCODE Patient Bundle for a given Patient
.... 18.12 Search by code:in in Conditions
.... 18.13 Cancer Risk Assessment Profile
.... 18.14 Cancer Stage Profile
.... 18.15 Parent for T, N, and M Categories.
.... 18.16 ALL Risk Assessment Profile
.... 18.17 Body Surface Area
.... 18.18 Cancer Disease Status Profile
.... 18.19 Cancer Patient Profile
.... 18.20 Cancer-Related Medication Administration Profile
.... 18.21 Cancer-Related Medication Request Profile
.... 18.22 Cancer-Related Surgical Procedure Profile
.... 18.23 CLL Binet Stage Profile
.... 18.24 CLL Rai Stage Profile
.... 18.25 Comorbidities Profile
.... 18.26 Deauville Scale Profile
.... 18.27 ECOG Performance Status Profile
.... 18.28 Genomic Region Studied Profile
.... 18.29 Genomic Variant Profile
.... 18.30 Genomics Report Profile
.... 18.31 Gynecologic Tumor FIGO Stage Profile
.... 18.32 Histologic Behavior and Type
.... 18.33 Histologic Grade
.... 18.34 History of Metastatic Cancer
.... 18.35 Human Specimen Profile
.... 18.36 Karnofsky Performance Status Profile
.... 18.37 Lansky Play Performance Status Profile
.... 18.38 Lymphoma Stage Profile
.... 18.39 mCODE Patient Bundle Profile
.... 18.40 mCODE Patient Group Profile
.... 18.41 Melanoma Breslow Depth Stage Profile
.... 18.42 Melanoma Clark Level Profile
.... 18.43 Myeloma ISS Stage Profile
.... 18.44 Myeloma RISS Stage Profile
.... 18.45 Neuroblastoma INRGSS Stage Profile
.... 18.46 Neuroblastoma INSS Stage Profile
.... 18.47 Primary Cancer Condition Profile
.... 18.48 Prostate Gleason Grade Group Profile
.... 18.49 Radiotherapy Course Summary Profile
.... 18.50 Radiotherapy Volume Profile
.... 18.51 Rhabdomyocaroma Clinical Group Stage Profile
.... 18.52 Rhabdomyocaroma Risk Assessment Profile
.... 18.53 Secondary Cancer Condition Profile
.... 18.54 TNM Distant Metastases Category Profile
.... 18.55 TNM Primary Tumor Category Profile
.... 18.56 TNM Regional Nodes Category Profile
.... 18.57 TNM Stage Group Profile
.... 18.58 Tumor Marker Test Profile
.... 18.59 Tumor Morphology Report
.... 18.60 Tumor Profile
.... 18.61 Tumor Size Profile
.... 18.62 Wilms Tumor Stage Profile
.... 18.63 Body Structure Identifier Profile
.... 18.64 Body Location Qualifier Extension
.... 18.65 Cancer Disease Status Evidence Type Extension
.... 18.66 Histology-Morphology-Behavior Extension
.... 18.67 Laterality Qualifier Extension
.... 18.68 Normalization Basis Extension
.... 18.69 Procedure Intent Extension
.... 18.70 Radiotherapy Dose Delivered To Volume Extension
.... 18.71 Radiotherapy Modality And Technique Extension
.... 18.72 Radiotherapy Modality Extension
.... 18.73 Radiotherapy Number of Sessions Extension
.... 18.74 Radiotherapy Technique Extension
.... 18.75 Related Condition Absent Extension
.... 18.76 Related Condition Extension
.... 18.77 Treatment Termination Reason Extension (deprecated)
.... 18.78 Acute Lymphoblastic Leukemia (ALL) Risk Assessment Value Set
.... 18.79 Benign Neoplasm of Brain and CNS Disorder Value Set
.... 18.80 Binet Stage Value Set
.... 18.81 Body Location and Laterality Qualifier Value Set
.... 18.82 Body Location Qualifier Value Set
.... 18.83 Brachytherapy High Dose Rate Electronic Technique Value Set
.... 18.84 Brachytherapy High Dose Rate Technique Value Set
.... 18.85 Brachytherapy Low Dose Rate Temporary Radation Technique Value Set
.... 18.86 Brachytherapy Modality Value Set
.... 18.87 Brachytherapy Permanent Seeds Technique Value Set
.... 18.88 Brachytherapy Pulsed Dose Rate Technique Value Set
.... 18.89 Brachytherapy Radiopharmaceutical Technique Value Set
.... 18.90 Brachytherapy Technique Value Set
.... 18.91 Breslow Depth Stage Value Set
.... 18.92 Cancer Body Location Value Set
.... 18.93 Cancer Disease Status Evidence Type Value Set
.... 18.94 Cancer Disorder Value Set
.... 18.95 Cancer Stage Type Value Set
.... 18.96 Cancer Stage Value Set
.... 18.97 Cancer Staging Method Value Set
.... 18.98 Cancer-Related Surgical Procedure Value Set
.... 18.99 Carbon Ion Beam Technique Value Set
.... 18.100 Carcinoma In-Situ Disorder Value Set
.... 18.101 Clark Level Value Set
.... 18.102 Clinical or Pathologic Modifier
.... 18.103 Condition Status Trend Maximum Value Set
.... 18.104 Condition Status Trend Value Set
.... 18.105 Cytologic Evidence of Malignancy Value Set
.... 18.106 Deauville Scale Value Set
.... 18.107 Electron Beam Technique Value Set
.... 18.108 FAB Classification Value
.... 18.109 FIGO Stage Value Set
.... 18.110 FIGO Staging Method Value Set
.... 18.111 Gleason Grade Value Set
.... 18.112 Histologic Behavior and Type Value Set
.... 18.113 Histologic Grade Value Set
.... 18.114 Histologic Grading System Value Set
.... 18.115 Histology Morphology Behavior Value Set
.... 18.116 History of Metastatic Malignant Neoplasm Value Set
.... 18.117 Human Specimen Type Value Set
.... 18.118 International Neuroblastoma Risk Group Staging System (INRGSS) for Neuroblastoma Risk Assessment Value Set
.... 18.119 International Neuroblastoma Staging System (INSS) for Neuroblastoma Stage Value Set
.... 18.120 International Staging System (ISS) for Myeloma Stage Value Set
.... 18.121 Lansky Play Performance Status VS
.... 18.122 Laterality Qualifier Value Set
.... 18.123 Lymphoma Stage Bulky Modifier Value Set
.... 18.124 Lymphoma Stage Value Modifier Value Set
.... 18.125 Lymphoma Stage Value Set
.... 18.126 Lymphoma Staging System Value Set
.... 18.127 Melanoma In-Situ Disorder Value Set
.... 18.128 Neutron Beam Technique Value Set
.... 18.129 Normalization Basis Value Set
.... 18.130 Photon Beam Technique Value Set
.... 18.131 Primary Cancer Disorder Value Set
.... 18.132 Primary Malignant Neoplasm Disorder Value Set
.... 18.133 Procedure Intent Value Set
.... 18.134 Proton Beam Technique Value Set
.... 18.135 Radiotherapy Modality Value Set
.... 18.136 Radiotherapy Technique Value Set
.... 18.137 Radiotherapy Treatment Location Qualifier Value Set
.... 18.138 Radiotherapy Treatment Location Value Set
.... 18.139 Radiotherapy Volume Type Value Set
.... 18.140 Rai Stage Value Set
.... 18.141 Rai Staging System Value Set
.... 18.142 Revised International Staging System (ISS) for Multiple Myeloma Stage Value Set
.... 18.143 Rhabdomyosarcoma Assessment Value Set
.... 18.144 Rhabdomyosarcoma Clinical Group Value
.... 18.145 Risk Assessment Type Value Set
.... 18.146 Risk Assessment Value Set
.... 18.147 Secondary Cancer Disorder Value Set
.... 18.148 Specific Diagnosis of Cancer Value Set
.... 18.149 Teleradiotherapy Modality Value Set
.... 18.150 Teleradiotherapy Technique Value Set
.... 18.151 TNM Distant Metastases Category Value Set
.... 18.152 TNM Distant Metastases Maximum Value Set
.... 18.153 TNM Distant Metastases Staging Type Maximum Value Set
.... 18.154 TNM Distant Metastases Staging Type Value Set
.... 18.155 TNM Primary Tumor Category Value Set
.... 18.156 TNM Primary Tumor Maximum Value Set
.... 18.157 TNM Primary Tumor Staging Type Maximum Value Set
.... 18.158 TNM Primary Tumor Staging Type Value Set
.... 18.159 TNM Regional Nodes Category Value Set
.... 18.160 TNM Regional Nodes Maximum Value Set
.... 18.161 TNM Regional Nodes Staging Type Maximum Value Set
.... 18.162 TNM Regional Nodes Staging Type Value Set
.... 18.163 TNM Stage Group Maximum Value Set
.... 18.164 TNM Stage Group Staging Type Maximum Value Set
.... 18.165 TNM Stage Group Staging Type Value Set
.... 18.166 TNM Stage Group Value Set
.... 18.167 TNM Staging Method Value Set
.... 18.168 Treatment Termination Reason Value Set
.... 18.169 Tumor Marker Test Value Set
.... 18.170 Tumor Morphology Code Max Value Set
.... 18.171 Tumor Morphology Code Value Set
.... 18.172 Tumor Size Method Value Set
.... 18.173 Tumor Size Units Value Set
.... 18.174 Wilms Tumor Body Site Value Set
.... 18.175 Wilms Tumor Stage Value Set
.... 18.176 Requested SNOMED Codes Code System
.... 18.177 TG263 Concept Map
.... 18.178 all-risk-assessment-high
.... 18.179 all-risk-assessment-standard-brian-l
.... 18.180 binet-stage-group-B
.... 18.181 body-surface-area-brian-l
.... 18.182 body-surface-area-example
.... 18.183 bodyheight-jenny-m-2018-03-06
.... 18.184 bodyweight-jenny-m-2018-03-16
.... 18.185 bodyweight-jenny-m-2018-04-22
.... 18.186 bone-marrow-aspirate-result-brian-l
.... 18.187 bone-marrow-biopsy-result-brian-l
.... 18.188 cancer-disease-status-improved
.... 18.189 cancer-disease-status-improved-brian-l
.... 18.190 cancer-disease-status-jenny-m
.... 18.191 cancer-patient-adam-everyman
.... 18.192 cancer-patient-brian-l
.... 18.193 cancer-patient-eve-anyperson
.... 18.194 cancer-patient-jenny-m
.... 18.195 cancer-patient-john-anyperson
.... 18.196 cancer-patient-lucy-child
.... 18.197 cancer-related-comorbidities-jenny-m
.... 18.198 cancer-related-comorbidities-john-anyperson
.... 18.199 cancer-related-medication-admin-cyclophosphamide-brian-l
.... 18.200 cancer-related-medication-admin-cyclophosphamide-jenny-m
.... 18.201 cancer-related-medication-admin-doxorubicin-jenny-m
.... 18.202 cancer-related-medication-admin-idarubicin-brian-l
.... 18.203 cancer-related-medication-admin-paclitaxel-jenny-m
.... 18.204 cancer-related-medication-admin-prednisone-brian-l
.... 18.205 cancer-related-medication-admin-vincristine-brian-l
.... 18.206 cancer-related-medication-request-anastrozole-jenny-m
.... 18.207 cancer-related-medication-request-cisplatin
.... 18.208 cancer-related-medication-request-cisplatin-stopped
.... 18.209 cancer-related-medication-request-cyclophosphamide-brian-l
.... 18.210 cancer-related-medication-request-cyclophosphamide-jenny-m
.... 18.211 cancer-related-medication-request-doxorubicin-jenny-m
.... 18.212 cancer-related-medication-request-gefitinib
.... 18.213 cancer-related-medication-request-idarubicin-brian-l
.... 18.214 cancer-related-medication-request-paclitaxel-jenny-m
.... 18.215 cancer-related-medication-request-prednisone-brian-l
.... 18.216 cancer-related-medication-request-vincristine-brian-l
.... 18.217 cancer-related-surgical-procedure-jenny-m
.... 18.218 cancer-related-surgical-procedure-lobectomy
.... 18.219 deauville-scale-five
.... 18.220 ecog-performance-status-fully-active
.... 18.221 ecog-performance-status-jenny-m
.... 18.222 family-member-history-aunt-jenny-m
.... 18.223 family-member-history-grandmother-brian-l
.... 18.224 family-member-history-sister-jenny-m
.... 18.225 family-member-history-uncle-jenny-m
.... 18.226 figo-stage-IIIA
.... 18.227 genomic-region-studied-jenny-m
.... 18.228 genomic-region-studied-stk11
.... 18.229 genomic-variant-fusion
.... 18.230 genomic-variant-germline-deletion
.... 18.231 genomic-variant-jenny-m
.... 18.232 genomic-variant-somatic-single-nucleotide
.... 18.233 genomics-report-jenny-m
.... 18.234 genomics-report-john-anyperson
.... 18.235 gleason-grade-group-4
.... 18.236 gx-cancer-patient-adam-anyperson
.... 18.237 gx-genomic-bundle-adam-anyperson
.... 18.238 gx-genomic-diagnostic-implication-bap1
.... 18.239 gx-genomic-diagnostic-implication-pof1b
.... 18.240 gx-genomic-diagnostic-implication-polrmt
.... 18.241 gx-genomic-msi
.... 18.242 gx-genomic-specimen-tumornormal-normal
.... 18.243 gx-genomic-specimen-tumornormal-tumor
.... 18.244 gx-genomic-therapeutic-implication-alectinib
.... 18.245 gx-genomic-therapeutic-implication-brigatinib
.... 18.246 gx-genomic-therapeutic-implication-ceritinib
.... 18.247 gx-genomic-therapeutic-implication-crizotinib
.... 18.248 gx-genomic-therapeutic-implication-lorlatinib
.... 18.249 gx-genomic-tmb
.... 18.250 gx-genomic-variant-fusion-ETV6-RUNX1-brian-l
.... 18.251 gx-genomic-variant-fusion-met-alk
.... 18.252 gx-genomic-variant-pertinent-negative-nras-kit-braf
.... 18.253 gx-genomic-variant-somatic-bap1-indel
.... 18.254 gx-genomic-variant-somatic-cdkn2a-cnv
.... 18.255 gx-genomic-variant-somatic-cdkn2b-cnv
.... 18.256 gx-genomic-variant-somatic-kdm5d
.... 18.257 gx-genomic-variant-somatic-mtap
.... 18.258 gx-genomic-variant-somatic-mycn
.... 18.259 gx-genomic-variant-somatic-pof1b
.... 18.260 gx-genomic-variant-somatic-polrmt
.... 18.261 gx-genomics-report-adam-anyperson
.... 18.262 gx-order-tumornormal-gensop-inc
.... 18.263 gx-practitioner-test-pathologist
.... 18.264 gx-us-core-organization-gensop-inc
.... 18.265 hematocrit-brian-l
.... 18.266 hemoglobin-brian-l
.... 18.267 histologic-behavior-and-type-non-small-cell
.... 18.268 histologic-grade-intermediate
.... 18.269 history-of-cancer-metastatic-to-liver
.... 18.270 hodgkins-lymphoma-stage-IIIe
.... 18.271 human-specimen-left-breast-jenny-m
.... 18.272 human-specimen-lung
.... 18.273 immunophenotype-brian-l
.... 18.274 jenny-m-chest-wall-lymph-nodes-treatment-volume
.... 18.275 jenny-m-chest-wall-treatment-volume
.... 18.276 john-anyperson-chf
.... 18.277 john-anyperson-hd
.... 18.278 john-anyperson-treatment-volume
.... 18.279 karnofsky-performance-status-normal-activity
.... 18.280 lab-result-observation-hemoglobin
.... 18.281 lansky-performance-status-brian-l
.... 18.282 lansky-play-performance-status-twenty
.... 18.283 mCODE Patient Group Example
.... 18.284 mcode-patient-bundle-jenny-m
.... 18.285 melanoma-breslow-depth-stage
.... 18.286 melanoma-clark-level-4
.... 18.287 multiple-myeloma-iss-stage-II
.... 18.288 multiple-myeloma-riss-stage-II
.... 18.289 neuroblastoma-inrgss-stage-MS
.... 18.290 neuroblastoma-inss-stage-III
.... 18.291 no-history-of-metastatic-cancer
.... 18.292 observation-smoking-pack-years-jenny-m
.... 18.293 primary-cancer-condition-breast
.... 18.294 primary-cancer-condition-brian-l
.... 18.295 primary-cancer-condition-cll
.... 18.296 primary-cancer-condition-jenny-m
.... 18.297 primary-cancer-condition-nonspecific
.... 18.298 primary-cancer-condition-nsclc
.... 18.299 radiotherapy-treatment-summary-chest-wall-jenny-m
.... 18.300 radiotherapy-treatment-summary-other-with-text
.... 18.301 rai-stage-II
.... 18.302 rhabdomyosarcoma-clinical-group-stage-IA
.... 18.303 rhabdomyosarcoma-risk-assessment-low
.... 18.304 secondary-cancer-condition-brain-mets
.... 18.305 tnm-clinical-distant-metastases-category-cM0
.... 18.306 tnm-clinical-distant-metastases-category-jenny-m
.... 18.307 tnm-clinical-primary-tumor-category-cT3
.... 18.308 tnm-clinical-primary-tumor-category-jenny-m
.... 18.309 tnm-clinical-regional-nodes-category-cN3
.... 18.310 tnm-clinical-regional-nodes-category-jenny-m
.... 18.311 tnm-clinical-stage-group-3c
.... 18.312 tnm-clinical-stage-group-jenny-m
.... 18.313 tnm-pathologic-distant-metastases-category-jenny-m
.... 18.314 tnm-pathologic-primary-tumor-category-jenny-m
.... 18.315 tnm-pathologic-regional-nodes-category-jenny-m
.... 18.316 tnm-pathologic-stage-group-jenny-m
.... 18.317 tumor-lobular-carcinoma-left-breast
.... 18.318 tumor-marker-test-egf
.... 18.319 tumor-marker-test-er-jenny-m
.... 18.320 tumor-marker-test-her2-jenny-m
.... 18.321 tumor-marker-test-oncotype-dx-jenny-m
.... 18.322 tumor-marker-test-pr-jenny-m
.... 18.323 tumor-morphology-report-non-small-cell-intermediate-grade
.... 18.324 tumor-size-jenny-m
.... 18.325 tumor-size-pathology
.... 18.326 tumor-specimen-left-breast-jenny-m
.... 18.327 tumor-specimen-lobular-carcinoma-left-breast
.... 18.328 us-core-condition-anxiety-jenny-m
.... 18.329 us-core-condition-atrial-septal-defect-brian-l
.... 18.330 us-core-condition-depression-jenny-m
.... 18.331 us-core-condition-hypertension-jenny-m
.... 18.332 us-core-diagnosticreport-cbc-brian-l
.... 18.333 us-core-diagnosticreport-lab-jenny-m
.... 18.334 us-core-lumbar-puncture-result-brian-l
.... 18.335 us-core-observation-lab-neutrophils-jenny-m
.... 18.336 us-core-observation-lab-sentinel-nodes-jenny-m
.... 18.337 us-core-observation-lab-tumor-dcis-jenny-m
.... 18.338 us-core-observation-lab-tumor-grade-jenny-m
.... 18.339 us-core-observation-lab-tumor-invasion-jenny-m
.... 18.340 us-core-observation-lab-tumor-margins-jenny-m
.... 18.341 us-core-organization-bedrock-medicine
.... 18.342 us-core-organization-physician-services-inc
.... 18.343 us-core-practitioner-jane-radiotech
.... 18.344 us-core-practitioner-kyle-anydoc
.... 18.345 us-core-practitioner-mary-obgyn
.... 18.346 us-core-practitioner-nancy-oncology-nurse
.... 18.347 us-core-practitioner-owen-oncologist
.... 18.348 us-core-practitioner-peter-pathologist
.... 18.349 us-core-procedure-biopsy-jenny-m
.... 18.350 us-core-procedure-bone-marrow-aspiration-brian-l
.... 18.351 us-core-procedure-bone-marrow-biopsy-brian-l
.... 18.352 us-core-procedure-lumbar-puncture-brian-l
.... 18.353 us-core-procedure-mammogram-jenny-m
.... 18.354 us-core-smokingstatus-jenny-m
.... 18.355 white-blood-cell-brian-l
.... 18.356 wilms-tumor-stage-III
... 19 Basic Examples
... 20 Genomics Examples
... 21 Extended Example
... 22 Extended Pediatric Example
... 23 Release Notes
... 24 Glossary
... 25 Download Specification
... 26 mCODE Implementation Guide Resource